test

Dr. Jeffrey R. Jay, M.D.

@Great Point Partners Llc

Latest period2024 - Q3ReportedManaged Assets$339.762MTotal holdings29
Assets growth rate-34.91%Assets growth rate (2-Q avg)-26.77%Continuous growth in asset value0 quarters

Portfolio positions

This chart displays the top 10 holdings in Great Point Partners Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 29 positions.

Assets under management

The assets under management (AUM) of Great Point Partners Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 339.762M in assets, with a quarterly growth rate of -34.91% and a 2-quarter average growth rate of -26.77%. The portfolio is managed by Dr. Jeffrey R. Jay, M.D., and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
NGNENeurogene Inc
Recent Activity
12.41%
$42.14M
1.004M shares@ $41.96 avg price
ABVXAbivax Sa
Recent Activity
Decreased -13.89%
7.22%
$24.523M
2.129M shares@ $11.53 avg price
PLRXPliant Therapeutics Inc
Recent Activity
Decreased -27.56%
6.31%
$21.412M
1.91M shares@ $11.21 avg price
EOLSEvolus Inc
Recent Activity
Decreased -52.27%
5.58%
$18.954M
1.17M shares@ $16.2 avg price
VRDNViridian Therapeutics Inc
Recent Activity
Increased 50%
5.03%
$17.062M
750,000 shares@ $22.75 avg price
ACLXArcellx Inc
Recent Activity
Decreased -59.34%
4.92%
$16.702M
200,000 shares@ $83.51 avg price
CYTKCytokinetics Inc
Recent Activity
Decreased -33.36%
4.92%
$16.685M
316,000 shares@ $52.8 avg price
KALVKalvista Pharmaceuticals Inc
Recent Activity
Decreased -2.91%
4.43%
$15.048M
1.3M shares@ $11.59 avg price
DVAXDynavax Technologies Corp
Recent Activity
Decreased -44.13%
4.35%
$14.774M
1.326M shares@ $11.15 avg price
CNTXContext Therapeutics Inc
Recent Activity
Decreased -6.52%
4.01%
$13.593M
6.935M shares@ $1.97 avg price